@WarClandestine If something sounds too good to be true, it probably is, which suggests that this situation is likely more jawboning by Trump ( I'm sure his birthday has nothing to do with it too ๐ค).
@JavierBlas So, just another "jawboning" Trump Iran deal is close post (I've lost track of how many now) with media and markets still foolishly believing it. Fool me once shame on you, Fool me twice or much more shame on me.
@RedWavePress So, just another "jawboning" Trump Iran deal is close post (I've lost track of how many now) with media and markets still foolishly believing it. Fool me once shame on you, Fool me twice or much more shame on me.
@SenatorTimScott@BankingGOP How about taking the damn action of scheduling the mark up vote and stop just talking about it. Your snail pace of doing this Clarity Act legislation is getting really old and every day that goes by with NOTHING but just talk makes you all even more useless than you already are.
$ARDX
MUST READ to the end!
Strategic tea leaves are getting interesting to say the least ๐ฅ
Strong Ibsrela momentum (path to $1B), explosive call options flow (7k+ calls in one session recently โ 267% above average daily volume), and analyst enthusiasm on the commercial ramp.
But the real intrigue? Zydus Lifesciences already working with JPM, Jefferies & IIFL on QIP funding - just incorporated Zara Merger SUB Inc. (Delaware entity, April 24).
Textbook M&A vehicle naming.
Meanwhile, Ardelyx quietly BURIES Morgan Stanley & Co. LLC as financial advisor in its latest earnings releaseโฆ plus the MARA acronym now surfacing in fresh SEC filings and board-level docs.
Another classic pre-merger breadcrumb?
And get this - Morgan Stanley and JPM have literally just teamed up (and squared off) on massive recent pharma deals like BioMarinโs $4.8B Amicus Therapeutics buyout & Sun Pharmaโs $11.75B Organon takeover.
๐ฅBanks donโt get paired on these files by accident.๐ฅ
Cross-border biotech consolidation play? ๐ง
US specialty assets + Zydus growth ambitions = interesting math.
Not saying a deal is done, or will be, but the pieces (and options market) are aligning in classic pre-M&A fashion.
Standalone growth story remains solid either way.
Xphozah concerns easily covered in CRVs to align.
Chairman Mott is likely salivating as he purchased shares numerous times at the market prices AND is a master negotiator.
How good is Mott at M&A ?
In 2007, David Mott then President & CEO of MedImmune sold the company to AstraZeneca in a $15.6 billion all-cash deal which was:
โTHE LARGEST biotech acquisition of the year and one of the biggest American biotech purchases EVER at the time.โ
It was a landmark cross-border biologics play that gave Mott deep, hands-on M&A experience with top-tier banks and Big Pharma buyers.โโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโโ
๐ฅ :)
@JoshYoung@MarketWatch More likely wouldn't happen this weekend due Trump doesn't want people distracted away from his Superbowl interview segment ๐
@SpeakerJohnson@realDonaldTrump What a crock of horse sh!t. You really should have said Trump/GOP helped Mideast energy dominance by NOT enforcing Russian, Iranain, etc.. oil sanctions all while causing a war on American energy companies by raising their drilling costs causing manpower layoffs.
@trevortombe@SheDrills The S&P 500 has been trading above the avg P/E valuation level for estimated fwd earnings the past 2+ yrs. Today's selloff may have used Trump's tariff policy as part of an excuse to be part of a well needed and justified correction. I won't be surprised if the selloff continues.
@MediasLies KJP is irrelevant and it is beyond logical reasoning why she is getting ANY media attention, even if it's just liberal biased shows like The View. ๐คฎ
@nbcsnl Except for the jeans and t-shirt bit with Mike Myers playing Elon with chainsaw, this opening skit was NOT even remotely satire or funny. It was actually just a stupid attempt by libitard SNL writers to push anti Trump propaganda. ๐คฎ๐คฎ๐คฎ